GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of IMVT
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Immunovant, Inc. stock price ended at $28.32 on Thursday, after losing 0.387%.
(Updated on Apr 18, 2024)

Sell candidate since Apr 16, 2024 Loss -6.84% PDF

The Immunovant, Inc. stock price fell by -0.387% on the last day (Thursday, 18th Apr 2024) from $28.43 to $28.32. It has now fallen 3 days in a row. During the last trading day the stock fluctuated 4.39% from a day low at $27.99 to a day high of $29.22. The price has fallen in 7 of the last 10 days and is down by -8.17% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -613 thousand shares and in total, 1 million shares were bought and sold for approximately $33.74 million.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -23.62% during the next 3 months and, with a 90% probability hold a price between $20.24 and $24.84 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

IMVT Signals & Forecast

There are few to no technical positive signals at the moment. The Immunovant, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $29.80 and $31.57. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, March 21, 2024, and so far it has fallen -14.42%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for Immunovant, Inc. stock

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $1.23 between high and low, or 4.39%. For the last week, the stock has had daily average volatility of 5.32%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (IMVT) For The Upcoming Trading Day Of Friday 19th

For the upcoming trading day on Friday, 19th we expect Immunovant, Inc. to open at $28.51, and during the day (based on 14 day Average True Range), to move between $26.80 and $29.84, which gives a possible trading interval of +/-$1.52 (+/-5.37%) up or down from last closing price. If Immunovant, Inc. takes out the full calculated possible swing range there will be an estimated 10.74% move between the lowest and the highest trading price during the day.

With no support below and resistance from accumulated volume @ $28.43, some $0.110 (0.39%) from the current price of $28.32, our system finds the risk reward not very attractive.

Is Immunovant, Inc. stock A Buy?

Immunovant, Inc. holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -1.787 Sell Candidate Unchanged

Predicted Opening Price for Immunovant, Inc. of Friday, April 19, 2024

Fair opening price April 19, 2024 Current price
$28.51 ( 0.671%) $28.32

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for IMVT

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 29.74 5.01 %
R2 29.27 3.36 %
R1 28.98 2.33 %
Current price: 28.32
Support S1 28.04 -0.99 %
S2 27.75 -2.01 %
S3 27.28 -3.67 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 33.09 16.84 %
R2 33.06 16.74 %
R1 28.43 0.388 %
Current price 28.32
Support S1 0 .
S2 0 .
S3 0 .

FAQ

What is the symbol for Immunovant, Inc. Stock and on which exchange is it traded?
The symbol for Immunovant, Inc. is IMVT and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Immunovant, Inc. Stock?
Immunovant, Inc. holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Immunovant, Inc. Stock?
Immunovant, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Immunovant, Inc. Stock.

What's the current price of Immunovant, Inc. Stock?
As of the end of day on the 2024-04-18, the price of an Immunovant, Inc. (IMVT) share was $28.32.

What is the 52-week high and low for Immunovant, Inc. Stock?
The 52-week high for Immunovant, Inc. Stock is $45.58 and the 52-week low is $15.08.

What is the market capitalization of Immunovant, Inc. Stock?
As of the 2024-04-18, the market capitalization of Immunovant, Inc. is 4.131B.

When is the next earnings date for Immunovant, Inc.?
The upcoming earnings date for Immunovant, Inc. is May 27, 2024.
Click to get the best stock tips daily for free!

About Immunovant, Inc.

Immunovant. Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for... IMVT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT